Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Enlivex Therapeutics Ltd., a foreign private issuer organized under Israeli law, covers the month of November 2025. The report details the status of the Company's 2025 Annual General Meeting of Shareholders held on November 10, 2025.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding a shareholder meeting and contains no financial statements or performance data.
Material Changes
The primary material event reported is the adjournment of the 2025 Annual General Meeting due to a lack of quorum on November 10, 2025. No financial or operational changes compared to prior periods are disclosed in this document.
Outlook, Risks, and Unusual Items
The Company has reconvened the Annual Meeting for Monday, November 17, 2025, at 7:00 p.m. Israel time at its principal executive offices in Nes Ziona, Israel. Voting deadlines have been extended as follows:
- Mailed Proxy Deadline: November 14, 2025, by 7:00 p.m. Israel time.
- Telephone/Internet Voting Deadline: November 13, 2025, by 11:59 p.m. Eastern time.
- Electronic Voting (TASE): Up to six hours before the adjourned meeting (by 1:00 p.m. Israel time on November 17, 2025).
Shareholders holding shares through the Tel Aviv Stock Exchange may vote in person, by proxy, or electronically via the Israel Securities Authority system.
Key Facts for Investor Verification
- The 2025 Annual General Meeting was adjourned due to a lack of quorum.
- The reconvened meeting is scheduled for November 17, 2025.
- Specific voting deadlines and methods have been updated for the adjourned meeting.
- This filing contains no financial performance data or updated business outlook.